30

Jiangxi Fushine Pharmaceutical Co LtdSHE 300497 Stock Report

Last reporting period 30 Sep, 2023

Updated 01 Nov, 2024

Last price

Market cap $B

0.226

Micro

Exchange

XSHE - Shenzhen Stock Exchange

300497.SZ Stock Analysis

30

Uncovered

Jiangxi Fushine Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-28/100

Low score

Market cap $B

0.226

Dividend yield

1.59 %

Shares outstanding

531.77 B

Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi and currently employs 1,849 full-time employees. The company went IPO on 2015-12-22. The firm's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The firm distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.

View Section: Eyestock Rating